Douglas R. Lowy

National Institutes of Health — United States

Medicine · Health Sciences

126h-index50.0kcitations558works5.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Cervical Cancer and HPV Research(188), Virus-based gene therapy research(112), Hepatitis B Virus Studies(92), Immunotherapy and Immune Responses(50), Animal Virus Infections Studies(37)

Publications544 total

Developing evidence‐based, cost‐effective <scp>P4</scp> cancer medicine for driving innovation in prevention, therapeutics, patient care and reducing healthcare inequalities
Molecular Oncology·2025Open Access
Noninferiority of One HPV Vaccine Dose to Two Doses
New England Journal of Medicine·2025· 11 cited
Post-attachment neutralization of HPV16 by antibodies derived from Gardasil-vaccinated women
npj Vaccines·2025Open Access
The impact of focused federal initiatives on pediatric cancer research
Cancer·2025Open Access
eIF2B Selectively Anchors and Activates Mutant KRAS
2025
Stat Bite: Urban and Rural Lung Cancer Mortality Trends in the United States
JNCI Journal of the National Cancer Institute·2025Open Access
Author response: The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells
2025Open Access
The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells
eLife·2025Open Access
Childhood cancer data initiative: expanded access to tumor molecular profiling for children, adolescents, and young adults
JNCI Journal of the National Cancer Institute·2025· 4 citedOpen Access
Urban–rural disparities in lung cancer incidence and mortality patterns in Black and White populations
Cancer·2025· 3 citedOpen Access
Human papillomavirus (HPV) type 16 and type 18 antibody concentrations after a single dose of bivalent HPV vaccine in girls aged 9–14 years compared with three doses of quadrivalent HPV vaccine in women aged 18–25 years in Costa Rica (PRIMAVERA): a non-randomised, open-label, immunobridging, non-inferiority trial
The Lancet Infectious Diseases·2025· 3 citedOpen Access
US cancer deaths prevented due to survival improvements stratified by extent of disease, 2010-2019
JNCI Journal of the National Cancer Institute·2025· 4 citedOpen Access
The lnc-FANCI-2 intrinsically restricts RAS signaling in HPV16-infected cervical cancer
2025Open Access
Author response: The lnc-FANCI-2 intrinsically restricts RAS signaling in HPV16-infected cervical cancer
2025Open Access
Abstract 4387: Identification of new drug combinations that cooperatively target KRAS-dependent nuclear protein export to treat mutant KRAS-driven pancreatic adenocarcinoma
Cancer Research·2025
SRSF3 is oncogenic in breast but tumor-suppressive in liver by differential regulation of gene expression
2025· 1 citedOpen Access
Human papillomavirus type 16 and 18 viral clearance and progression to precancer among women aged 18–25 years enrolled in the Costa Rica HPV prophylactic vaccine trial (CVT)
Vaccine·2025· 1 citedOpen Access
The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling in human papillomavirus type 16-infected cervical cancer cells
eLife·2024· 2 citedOpen Access
The long noncoding RNA lnc-FANCI-2 intrinsically restricts RAS signaling and phosphorylation of Akt and Erk in HPV16-infected cervical cancer
2024· 2 citedOpen Access
The pro-oncogenic noncanonical activity of a RAS•GTP:RanGAP1 complex facilitates nuclear protein export
Nature Cancer·2024· 9 citedOpen Access
page 1 of 28Next →

Frequent Co-authors

John T. Schiller(23), Edward M. Scolnick(8), Christopher B. Buck(7), Cynthia D. Thompson(6), Esther H. Chang(5), Reinhard Kirnbauer(5), Alex G. Papageorge(4), Berthe M. Willumsen(4), N L Hubbert(4), Ronald Ellis(4), Deborah DeFeo(3), Thomas Y. Shih(3), Matthew A. Gonda(3), Howard A. Young(3), Allan Hildesheim(3), Rolando Herrero(3), Sholom Wacholder(3), Ana Cecilia Rodríguez(3), Diane Solomon(3), Paula González(3)